Alvogen 
Welcome,         Profile    Billing    Logout  
 11 Products   71 Diseases   11 Products   16 Trials   2029 News 


12345678910111213...2627»
  • ||||||||||  Xenical (orlistat) / Roche, GSK, Saxenda (liraglutide 3 mg) / Novo Nordisk
    Review, Journal, HEOR:  Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review. (Pubmed Central) -  Apr 10, 2025   
    Topiramate, as an adjunct to lifestyle intervention, may be considered in the treatment of pediatric MASLD, specifically in the context of failed lifestyle modification and inability to tolerate or qualify for other obesity pharmacotherapy. This literature review evaluates and compares the effectiveness of four pharmacological agents semaglutide, liraglutide, orlistat, phentermine, and emerging agents like
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp
    Journal:  Discovery of the 2,3-Dihydrobenzopyrane-4-one as a Potent FTO Inhibitor against Obesity-Related Metabolic Diseases. (Pubmed Central) -  Apr 10, 2025   
    However, the existing FTO inhibitor entacapone has been limited in clinical application due to its low potency and short plasma elimination half-life...Surprisingly, eriodictyol showed good pharmacokinetic properties and no obvious toxicity. These results could provide the reference for design of new FTO inhibitors against obesity-related metabolic diseases.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
    Review, Journal:  Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems. (Pubmed Central) -  Apr 5, 2025   
    Infliximab-dyyb was the first biosimilar approved by US-FDA for IBD...It should be noted that more biologics are in the pipeline as golimumab and natalizumab patents are set to expire in the near future, and biosimilars are now in pre-clinical to phase 3 trials...Several drug delivery systems based on passive and active targeting mechanisms are under active investigation to overcome these limitations. This review sheds light on the emergence of biologics and biosimilars as alternatives in IBD management, the differences between them, challenges and risks, and future perspectives in IBD therapy and new trends in drug delivery systems.
  • ||||||||||  Imcivree (setmelanotide) / Rhythm Pharma
    Review, Journal:  Current and future state of pharmacological management of pediatric obesity. (Pubmed Central) -  Apr 5, 2025   
    This report additionally includes RCTs examining AOM for special populations of pediatric obesity including monogenic obesity, Bardet Biedl syndrome, Prader Willi syndrome, and hypothalamic obesity. Finally, the clinical application of AOM for children and adolescents, as well as future directions and challenges are discussed.
  • ||||||||||  Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    Enrollment closed, Trial completion date:  PRIME: IBD Disease Course of Infliximab-na (clinicaltrials.gov) -  Apr 2, 2025   
    P=N/A,  N=120, Active, not recruiting, 
    Finally, the clinical application of AOM for children and adolescents, as well as future directions and challenges are discussed. Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Nov 2025
  • ||||||||||  Gralise (gabapentin) / Alvogen
    Trial completion:  Preoperative Gabapentin vs Placebo for Vaginal Prolapse Surgery (clinicaltrials.gov) -  Mar 28, 2025   
    P4,  N=110, Completed, 
    Patients should consult a pharmacist or physician before using compound cold medicines to avoid the risk of adverse reactions caused by drug-drug interactions. Recruiting --> Completed
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly
    Reimbursement, US reimbursement, Journal:  Older Adults' Views on Insurance Coverage for Weight Management Medications. (Pubmed Central) -  Mar 26, 2025   
    In this survey study of older US adults, most participants agreed that Medicare should cover weight management medications and more than half of those with BMI of 30 or greater were interested in using them. These results should inform decisions to include weight management medications in the Medicare and commercial insurance programs, as well as utilization policies to control health care costs.
  • ||||||||||  Review, Journal:  Mechanisms and treatment of obesity-related hypertension-Part 2: Treatments. (Pubmed Central) -  Mar 25, 2025   
    Integrating a multifaceted weight-based approach with other strategies, such as antihypertensive drugs and renal denervation, could specifically target the main neuro-hormonal and renal pathophysiological mechanisms of obesity-related hypertension, including sympathetic-nervous and renin-angiotensin-aldosterone systems overactivity, salt retention, and volume expansion. This comprehensive strategy can provide a personalized algorithm for managing hypertension in obesity within the context of "precision medicine" principles.
  • ||||||||||  phentermine / Generic mfg., bupropion / Generic mfg., topiramate/phentermine / Generic mfg.
    Journal:  The Evolving Role of Weight Loss Pharmacotherapy. (Pubmed Central) -  Mar 21, 2025   
    Despite their effectiveness, barriers to widespread use include their cost, insurance approval, and side effect profile. Further studies are underway examining the role of pharmacotherapy in conjunction with endoscopic bariatric therapies as well as bariatric surgery.
  • ||||||||||  topiramate/phentermine / Generic mfg., Mounjaro (tirzepatide) / Eli Lilly
    Journal, HEOR, Cost-effectiveness:  Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. (Pubmed Central) -  Mar 14, 2025   
    This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices. Efforts to reduce the net prices of new antiobesity medications are essential to ensure equitable access to highly effective antiobesity medications.
  • ||||||||||  topiramate/phentermine / Generic mfg.
    The POuND OUT study: phentermine and topiramate for uric acid stone prevention (Galileo 1001; In Person) -  Mar 6, 2025 - Abstract #AUA2025AUA_2865;    
    Individuals on study drugs also had fewer stone procedures, lower HbA1c levels, and higher urine pH than controls. This data provides a framework to study the impact of this novel alternative UAN therapy in a wider range of obese and diabetic populations.
  • ||||||||||  Meridia (sibutramine) / AbbVie, Xenical (orlistat) / Roche, GSK, Byetta (exenatide) / AstraZeneca
    Clinical, Retrospective data, Review, Journal:  Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis. (Pubmed Central) -  Feb 27, 2025   
    These data represent the longest duration of "real-world" follow-up, and should provide further reassurance that nonmedical switching is safe and clinically comparable to ongoing originator infliximab in clinically stable patients with IBD. The study found that semaglutide outperformed other AOMs in reducing BMI and additional weight-related outcomes in children and adolescents with obesity, while PHEN/TPM showed comparable efficacy.
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp
    Trial completion date, Trial primary completion date:  [18F]F-DOPA Imaging in Patients with Autonomic Failure (clinicaltrials.gov) -  Feb 24, 2025   
    P1,  N=40, Recruiting, 
    This change has the potential for large cost savings. Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp
    Journal:  Roles of N6-Methyladenosine in LncRNA Changes and Oxidative Damage in Cadmium-Induced Pancreatic ?-cells. (Pubmed Central) -  Feb 12, 2025   
    In this study, m6A agonist entacapone and inhibitor 3-deazadenosine were used to identify the effects of m6A on cadmium-induced oxidative damage as well as LncRNA changes...In conclusion, our data revealed critical roles of m6A modification in cadmium-induced LncRNAs and oxidative damage. Our findings point to a new direction for future studies on the molecular mechanisms of pancreatic ?-cell damage induced by cadmium.
  • ||||||||||  Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
    Biosimilar but not quite the same?: Post-induction levels of infliximab differ between brands (Poster exhibition) -  Jan 11, 2025 - Abstract #ECCOIBD2025ECCO_IBD_1847;    
    This should be taken into consideration when considering higher dosing at induction or for those patients treated with infliximab for acute severe colitis and earlier accelerated dosing should be considered in those patients treated with Remsima who have a slow clinical response to treatment. Trough levels once established on the drug appear to be similar and rates of switching out of class due to failure to respond/loss of response and antibody formation comparable.
  • ||||||||||  Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
    Biosimilar Therapy in IBD: Real-World Evidence from Saudi Arabia (Poster exhibition) -  Jan 11, 2025 - Abstract #ECCOIBD2025ECCO_IBD_1702;    
    Conclusion Biosimilars are well tolerated and effective in achieving disease control, clinical response, and remission in Saudi Arabian patients with CD and UC. These findings support the use of CT-P13 as a cost-effective treatment option for IBD.
  • ||||||||||  Saxenda (liraglutide 3 mg) / Novo Nordisk
    Enrollment closed, Trial completion date, Trial primary completion date:  Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) -  Jan 10, 2025   
    P=N/A,  N=30, Active, not recruiting, 
    These findings support the use of CT-P13 as a cost-effective treatment option for IBD. Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly
    Review, Journal:  Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide. (Pubmed Central) -  Jan 6, 2025   
    Its Food and Drug Administration approval marks a milestone in the realm of obesity therapeutics. Going beyond a recapitulation of findings, the conclusion emphasizes the imperative for ongoing exploration and vigilant safety monitoring in tirzepatide's application.
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp
    Journal:  In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors. (Pubmed Central) -  Dec 27, 2024   
    Our study provides a foundational framework for the development of novel anticancer compounds able to target multiple pathways in cancer. Further preclinical and clinical investigations are needed to validate the efficacy of these compounds in clinical settings and to test their ability to overcome resistance and improve patient outcome.
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp
    Journal:  Biomimetic Approach for Optimal Designing of the Shape and Controlled Release of Therapeutics from Tricompartmental Microcarriers for Managing Parkinson's Disease. (Pubmed Central) -  Dec 11, 2024   
    Moreover, Poptimized exhibits ?100% encapsulation efficiency of all three PD drugs, with the cumulative release of ?100% LD, ?97% CD, and ?65% ENT within 5 h of the in vitro study. In addition, in vivo studies such as pharmacokinetics (using healthy rats) and pharmacodynamics [using the MPTP (methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-injected PD-induced mice model] showed that the TCM can effectively control the release of LD (primary drug) for a prolonged period, thereby promising sustained drug delivery and improved therapeutics outcomes.
  • ||||||||||  Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
    Enrollment change, Trial termination:  An Observational Study to Evaluate Safety and Efficacy of Remsima (clinicaltrials.gov) -  Dec 9, 2024   
    P=N/A,  N=329, Terminated, 
    In addition, in vivo studies such as pharmacokinetics (using healthy rats) and pharmacodynamics [using the MPTP (methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-injected PD-induced mice model] showed that the TCM can effectively control the release of LD (primary drug) for a prolonged period, thereby promising sustained drug delivery and improved therapeutics outcomes. N=1000 --> 329 | Recruiting --> Terminated; Terminated